卡塔尔波尔对心脑血管疾病的保护作用:综合性综述
Zixi Zhang1, Yongguo Dai2,3, Yichao Xiao1
1Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
卡塔尔波尔是一种天然化合物,通过减少炎症和氧化应激,有望保护心脑血管疾病 (CVD). 它的安全性概况表明,它有可能成为治疗心血管疾病的自然疗法.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心血管医学 心血管医学
- 自然产品化学 自然产品化学
背景情况:
- 心脑血管疾病 (CVD) 构成了全球严重的健康负担.
- 像Rehmannia glutinosa*中的catalpol这样的虹膜糖化物正在研究其治疗潜力.
- 了解自然化合物在心血管疾病治疗中的机制至关重要.
研究的目的:
- 审查最近关于catalpol对各种心血管疾病的保护作用的研究.
- 探索卡塔尔波尔心脏保护作用背后的分子机制.
- 评估catalpol作为心血管疾病天然治疗剂的潜力.
主要方法:
- 对卡塔波尔和心血管疾病的临床前研究的文献综述.
- 对调查catalpol抗氧化,抗炎和抗丧性质的研究进行分析.
- 检查由catalpol调制的信号通路.
主要成果:
- 在动脉样硬化,心肌缺血/心脏病发作,心脏缩和心力衰竭的模型中,Catalpol显示出保护作用.
- 关键机制包括抗氧化剂 (Nrf2/HO-1),抗炎 (NF-κB) 和抗亡途径.
- 卡塔尔波尔还显示在糖尿病心血管并发症和血栓形成方面有好处.
- 这涉及到像PGC-1α/TERT,PI3K/Akt,AMPK,ER和GRP78/PERK这样的信号通路.
结论:
- 卡塔尔波尔通过多个分子途径表现出治疗一系列心血管疾病的巨大潜力.
- 它的安全性和耐受性表明它可能是心血管疾病患者的宝贵辅助疗法.
- 需要进一步的临床研究来确定catalpol在人类心血管疾病治疗中的有效性.
更多相关视频
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
09:38Simultaneous Isolation of High Quality Cardiomyocytes, Endothelial Cells, and Fibroblasts from an Adult Rat Heart
Published on: May 19, 2017
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Heart Failure Drugs: β-Blockers
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
